KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Staar Surgical (STAA) Research & Development (2016 - 2026)

Staar Surgical (STAA) has disclosed Research & Development for 17 consecutive years, with $9.2 million as the latest value for Q1 2026.

  • For the quarter ending Q1 2026, Research & Development fell 5.39% year-over-year to $9.2 million, compared with a TTM value of $40.1 million through Jan 2026, down 15.79%, and an annual FY2026 reading of $40.1 million, down 11.61% over the prior year.
  • Research & Development was $9.2 million for Q1 2026 at Staar Surgical, roughly flat from $9.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $14.5 million in Q3 2024 and bottomed at $6.9 million in Q4 2023.
  • Average Research & Development over 5 years is $10.3 million, with a median of $9.8 million recorded in 2022.
  • The sharpest move saw Research & Development soared 40.73% in 2024, then tumbled 36.48% in 2025.
  • Year by year, Research & Development stood at $9.8 million in 2022, then decreased by 29.08% to $6.9 million in 2023, then surged by 40.73% to $9.8 million in 2024, then decreased by 5.75% to $9.2 million in 2025, then grew by 0.38% to $9.2 million in 2026.
  • Business Quant data shows Research & Development for STAA at $9.2 million in Q1 2026, $9.2 million in Q3 2025, and $7.9 million in Q2 2025.